Swedish Orphan Biovitrum and Dongbao announce Commercial Alliance for the Chinese and European markets
The announced Commercial Alliance would be a partnership where both parties will benefit in two ways. First, each party secures a marketing and sales partner for its own products in an important new territory, China in the case of Swedish Orphan Biovitrum and Europe in the case of Dongbao. Second, each party gains access to a new portfolio of exciting products for its home markets.
Martin Nicklasson, CEO of Swedish Orphan Biovitrum stated "We are very pleased to have identified a partner in Dongbao with a successful track record of selling high value biotechnology products in China. Dongbao has a deep understanding of biotechnology products from a manufacturing and clinical development perspective. Moreover, they have an impressive track record of success in regulatory affairs as well as in marketing and sales. Thus, we see Dongbao as the perfect partner to help Swedish Orphan Biovitrum to realize the significant opportunity for our products in the Chinese market.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.